Candriam S.C.A. cut its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 84.5% in the third quarter, Holdings Channel.com reports. The firm owned 73,402 shares of the company’s stock after selling 401,533 shares during the period. Candriam S.C.A.’s holdings in Zoetis were worth $5,144,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Uhlmann Price Securities LLC increased its position in shares of Zoetis by 77.9% during the 3rd quarter. Uhlmann Price Securities LLC now owns 5,158 shares of the company’s stock worth $360,000 after purchasing an additional 2,258 shares in the last quarter. Ethic Inc. lifted its holdings in Zoetis by 56.9% during the 3rd quarter. Ethic Inc. now owns 64,000 shares of the company’s stock valued at $4,469,000 after purchasing an additional 23,204 shares during the last quarter. 180 Wealth Advisors LLC lifted its holdings in Zoetis by 23.1% during the 3rd quarter. 180 Wealth Advisors LLC now owns 4,289 shares of the company’s stock valued at $299,000 after purchasing an additional 805 shares during the last quarter. Buckhead Capital Management LLC boosted its position in Zoetis by 9.6% in the third quarter. Buckhead Capital Management LLC now owns 44,359 shares of the company’s stock valued at $3,098,000 after buying an additional 3,890 shares in the last quarter. Finally, StoneX Group Inc. boosted its position in Zoetis by 7.8% in the third quarter. StoneX Group Inc. now owns 4,004 shares of the company’s stock valued at $286,000 after buying an additional 291 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.
Zoetis Stock Performance
Shares of ZTS stock opened at $82.48 on Wednesday. The company has a debt-to-equity ratio of 2.51, a current ratio of 2.35 and a quick ratio of 1.40. The stock has a market cap of $33.51 billion, a PE ratio of 12.42, a price-to-earnings-growth ratio of 1.19 and a beta of 0.67. The stock has a 50-day moving average of $75.88 and a 200-day moving average of $92.18. Zoetis Inc. has a one year low of $68.77 and a one year high of $132.49.
Zoetis (NYSE:ZTS – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, topping the consensus estimate of $1.51 by $0.24. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same period in the previous year, the company posted $1.70 earnings per share. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. As a group, sell-side analysts expect that Zoetis Inc. will post 6.29 earnings per share for the current year.
Zoetis Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.6%. Zoetis’s dividend payout ratio (DPR) is currently 36.05%.
Analyst Ratings Changes
Several analysts have recently weighed in on the stock. The Goldman Sachs Group began coverage on shares of Zoetis in a report on Friday, October 16th. They set a “neutral” rating and a $74.00 price objective for the company. Morgan Stanley reduced their target price on Zoetis from $85.00 to $82.00 and set an “overweight” rating on the stock in a report on Thursday, October 29th. TD Cowen reduced their target price on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Cantor Fitzgerald set a $94.00 price target on Zoetis in a research report on Tuesday, August 25th. Finally, UBS Group raised their price target on Zoetis from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Tuesday, October 27th. Eight investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $101.25.
Zoetis Company Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Featured Articles
- Five stocks we like better than Zoetis
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
